| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 56 | 2025 | 352 | 9.720 |
Why?
|
| Leukemia, Myeloid, Acute | 21 | 2025 | 193 | 6.100 |
Why?
|
| Graft vs Host Disease | 14 | 2025 | 113 | 2.880 |
Why?
|
| Myelodysplastic Syndromes | 14 | 2025 | 87 | 2.510 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 209 | 2.240 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 223 | 2.220 |
Why?
|
| Transplantation Conditioning | 26 | 2023 | 102 | 1.990 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 | 2019 | 46 | 1.890 |
Why?
|
| Betacoronavirus | 5 | 2020 | 182 | 1.560 |
Why?
|
| Pandemics | 8 | 2023 | 671 | 1.550 |
Why?
|
| Hematologic Neoplasms | 5 | 2020 | 49 | 1.540 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 663 | 1.410 |
Why?
|
| Transplantation, Homologous | 18 | 2025 | 245 | 1.240 |
Why?
|
| Humans | 113 | 2025 | 63443 | 1.230 |
Why?
|
| Multiple Myeloma | 8 | 2023 | 348 | 1.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2024 | 68 | 1.120 |
Why?
|
| Leukocytosis | 2 | 2020 | 15 | 1.040 |
Why?
|
| Hematology | 2 | 2022 | 12 | 0.920 |
Why?
|
| Aged | 45 | 2025 | 14446 | 0.900 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 188 | 0.870 |
Why?
|
| Staurosporine | 1 | 2024 | 20 | 0.850 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 448 | 0.850 |
Why?
|
| Stem Cell Transplantation | 4 | 2020 | 79 | 0.850 |
Why?
|
| Hematologic Diseases | 2 | 2020 | 12 | 0.840 |
Why?
|
| Middle Aged | 53 | 2025 | 17612 | 0.810 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2020 | 74 | 0.800 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 31 | 0.800 |
Why?
|
| Male | 57 | 2025 | 29889 | 0.790 |
Why?
|
| Mutation | 12 | 2025 | 2612 | 0.770 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 64 | 0.770 |
Why?
|
| Aged, 80 and over | 22 | 2025 | 5462 | 0.760 |
Why?
|
| Infection Control | 2 | 2020 | 106 | 0.760 |
Why?
|
| Splenic Infarction | 1 | 2021 | 1 | 0.730 |
Why?
|
| Paramyxoviridae Infections | 1 | 2021 | 7 | 0.720 |
Why?
|
| Thrombocytopenia | 2 | 2020 | 54 | 0.700 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2021 | 37 | 0.700 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 8 | 0.680 |
Why?
|
| Transplantation, Autologous | 9 | 2020 | 127 | 0.680 |
Why?
|
| Immunoconjugates | 1 | 2021 | 90 | 0.680 |
Why?
|
| Blood Donors | 1 | 2020 | 23 | 0.670 |
Why?
|
| Kidney Pelvis | 1 | 2020 | 13 | 0.670 |
Why?
|
| Hemolysis | 1 | 2020 | 40 | 0.670 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2020 | 4 | 0.670 |
Why?
|
| Complement Activation | 1 | 2020 | 47 | 0.660 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2020 | 16 | 0.660 |
Why?
|
| Strongyloides stercoralis | 1 | 2020 | 12 | 0.660 |
Why?
|
| Adult | 44 | 2025 | 16823 | 0.660 |
Why?
|
| Strongyloidiasis | 1 | 2020 | 10 | 0.660 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2020 | 14 | 0.660 |
Why?
|
| Sirolimus | 2 | 2017 | 93 | 0.630 |
Why?
|
| Leukemia, Lymphoid | 2 | 2013 | 11 | 0.630 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 175 | 0.620 |
Why?
|
| Quality of Life | 5 | 2023 | 1228 | 0.620 |
Why?
|
| Cyclophosphamide | 7 | 2025 | 82 | 0.620 |
Why?
|
| Female | 48 | 2025 | 32878 | 0.620 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 108 | 0.610 |
Why?
|
| Immunosuppressive Agents | 3 | 2025 | 378 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 724 | 0.610 |
Why?
|
| Survival Rate | 9 | 2025 | 851 | 0.610 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2025 | 97 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 238 | 0.570 |
Why?
|
| Young Adult | 20 | 2025 | 4694 | 0.550 |
Why?
|
| Antibodies, Monoclonal | 4 | 2023 | 864 | 0.540 |
Why?
|
| Treatment Outcome | 17 | 2025 | 5680 | 0.540 |
Why?
|
| Mycophenolic Acid | 1 | 2017 | 68 | 0.530 |
Why?
|
| Neoplasms | 4 | 2023 | 1364 | 0.530 |
Why?
|
| Prognosis | 13 | 2025 | 1748 | 0.520 |
Why?
|
| Recurrence | 10 | 2023 | 641 | 0.510 |
Why?
|
| Remission Induction | 5 | 2024 | 148 | 0.500 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2025 | 309 | 0.470 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2019 | 39 | 0.460 |
Why?
|
| Neoplastic Stem Cells | 3 | 2014 | 203 | 0.450 |
Why?
|
| Hodgkin Disease | 2 | 2020 | 55 | 0.450 |
Why?
|
| Translocation, Genetic | 2 | 2013 | 71 | 0.450 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 2 | 2004 | 10 | 0.420 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2013 | 5 | 0.410 |
Why?
|
| Polymerase Chain Reaction | 5 | 2009 | 517 | 0.400 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.390 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 51 | 0.390 |
Why?
|
| Adolescent | 18 | 2024 | 6245 | 0.390 |
Why?
|
| Survival Analysis | 8 | 2021 | 583 | 0.380 |
Why?
|
| Retrospective Studies | 14 | 2023 | 6658 | 0.380 |
Why?
|
| Primary Myelofibrosis | 2 | 2023 | 11 | 0.370 |
Why?
|
| Bone Marrow Cells | 7 | 2019 | 238 | 0.370 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 373 | 0.360 |
Why?
|
| Disease-Free Survival | 7 | 2022 | 242 | 0.360 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2012 | 284 | 0.350 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 281 | 0.340 |
Why?
|
| Busulfan | 5 | 2023 | 18 | 0.330 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2024 | 26 | 0.330 |
Why?
|
| Abdomen | 2 | 2020 | 91 | 0.320 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 49 | 0.320 |
Why?
|
| Bone Marrow Transplantation | 4 | 2007 | 139 | 0.320 |
Why?
|
| Cytokines | 3 | 2021 | 935 | 0.310 |
Why?
|
| Lymphoma, B-Cell | 1 | 2009 | 61 | 0.310 |
Why?
|
| Myocardial Stunning | 1 | 2009 | 6 | 0.300 |
Why?
|
| Dendritic Cells | 4 | 2023 | 525 | 0.300 |
Why?
|
| Cell Movement | 5 | 2010 | 453 | 0.300 |
Why?
|
| Coronary Vasospasm | 1 | 2009 | 11 | 0.300 |
Why?
|
| Osteoarthropathy, Secondary Hypertrophic | 1 | 2008 | 2 | 0.300 |
Why?
|
| Antigens, CD19 | 2 | 2025 | 23 | 0.300 |
Why?
|
| Vena Cava, Superior | 1 | 2008 | 9 | 0.300 |
Why?
|
| Cancer Survivors | 2 | 2022 | 115 | 0.300 |
Why?
|
| Disease Management | 2 | 2020 | 232 | 0.290 |
Why?
|
| Vena Cava Filters | 1 | 2008 | 23 | 0.290 |
Why?
|
| Foreign-Body Migration | 1 | 2008 | 23 | 0.290 |
Why?
|
| CD56 Antigen | 1 | 2008 | 17 | 0.290 |
Why?
|
| Rituximab | 3 | 2020 | 87 | 0.280 |
Why?
|
| Myeloproliferative Disorders | 2 | 2023 | 16 | 0.280 |
Why?
|
| Mitoxantrone | 2 | 2018 | 16 | 0.280 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 200 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 206 | 0.270 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 130 | 0.270 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2023 | 7 | 0.270 |
Why?
|
| Erythrocytes | 2 | 2020 | 149 | 0.270 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1553 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 345 | 0.260 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 222 | 0.260 |
Why?
|
| Leukemia | 2 | 2020 | 62 | 0.260 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 166 | 0.260 |
Why?
|
| Cell Lineage | 3 | 2007 | 270 | 0.250 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2005 | 53 | 0.250 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 173 | 0.250 |
Why?
|
| Stem Cells | 2 | 2004 | 259 | 0.240 |
Why?
|
| Bone Marrow | 4 | 2023 | 180 | 0.240 |
Why?
|
| Lupus Nephritis | 1 | 2025 | 35 | 0.240 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 44 | 0.230 |
Why?
|
| Melphalan | 5 | 2023 | 23 | 0.220 |
Why?
|
| Chromosome Aberrations | 2 | 2019 | 67 | 0.220 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 58 | 0.220 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.210 |
Why?
|
| Maintenance Chemotherapy | 2 | 2021 | 15 | 0.210 |
Why?
|
| Immunophenotyping | 4 | 2011 | 196 | 0.210 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 172 | 0.210 |
Why?
|
| Tissue Donors | 2 | 2023 | 153 | 0.200 |
Why?
|
| Immunization, Passive | 2 | 2020 | 105 | 0.200 |
Why?
|
| Cell Differentiation | 5 | 2018 | 1353 | 0.200 |
Why?
|
| Flow Cytometry | 5 | 2009 | 664 | 0.200 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 396 | 0.190 |
Why?
|
| DNA Methylation | 1 | 2004 | 292 | 0.190 |
Why?
|
| Acute Disease | 2 | 2023 | 671 | 0.190 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2022 | 2 | 0.190 |
Why?
|
| Bacterial Infections | 1 | 2023 | 149 | 0.190 |
Why?
|
| Toxocariasis | 1 | 2021 | 1 | 0.190 |
Why?
|
| Disease Progression | 3 | 2024 | 1172 | 0.180 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 674 | 0.180 |
Why?
|
| Parasites | 1 | 2021 | 16 | 0.180 |
Why?
|
| Cytarabine | 3 | 2020 | 36 | 0.180 |
Why?
|
| Chronic Disease | 2 | 2023 | 753 | 0.170 |
Why?
|
| Salvage Therapy | 1 | 2021 | 75 | 0.170 |
Why?
|
| Community Health Planning | 1 | 2020 | 16 | 0.170 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2020 | 6 | 0.170 |
Why?
|
| Platelet Count | 1 | 2020 | 26 | 0.170 |
Why?
|
| Convalescence | 1 | 2020 | 18 | 0.170 |
Why?
|
| Consolidation Chemotherapy | 1 | 2020 | 3 | 0.170 |
Why?
|
| Blood Banks | 1 | 2020 | 9 | 0.170 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 40 | 0.170 |
Why?
|
| Thiabendazole | 1 | 2020 | 3 | 0.170 |
Why?
|
| Enterococcus faecium | 1 | 2020 | 7 | 0.170 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2020 | 14 | 0.170 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2020 | 2 | 0.170 |
Why?
|
| Daptomycin | 1 | 2020 | 9 | 0.170 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.170 |
Why?
|
| Blood Cell Count | 1 | 2020 | 33 | 0.170 |
Why?
|
| Myeloablative Agonists | 1 | 2020 | 13 | 0.170 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 878 | 0.170 |
Why?
|
| Antiparasitic Agents | 1 | 2020 | 9 | 0.170 |
Why?
|
| Donor Selection | 1 | 2020 | 17 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 14 | 0.160 |
Why?
|
| Laser Therapy | 1 | 2020 | 42 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 49 | 0.160 |
Why?
|
| Transplant Recipients | 1 | 2020 | 35 | 0.160 |
Why?
|
| Ivermectin | 1 | 2020 | 24 | 0.160 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 43 | 0.160 |
Why?
|
| Biomarkers, Tumor | 3 | 2025 | 507 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 45 | 0.160 |
Why?
|
| Europe | 1 | 2020 | 195 | 0.160 |
Why?
|
| Bronchoscopy | 1 | 2020 | 90 | 0.160 |
Why?
|
| Chromatin | 1 | 2004 | 608 | 0.160 |
Why?
|
| China | 1 | 2020 | 162 | 0.160 |
Why?
|
| Risk Factors | 5 | 2020 | 5353 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2020 | 102 | 0.160 |
Why?
|
| Blood Transfusion | 1 | 2020 | 162 | 0.150 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 55 | 0.150 |
Why?
|
| Phenytoin | 1 | 2019 | 16 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 10 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2024 | 1186 | 0.150 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 9 | 0.150 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 210 | 0.150 |
Why?
|
| Ventricular Remodeling | 1 | 2019 | 83 | 0.150 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 35 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 41 | 0.150 |
Why?
|
| Cross Infection | 1 | 2020 | 164 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2014 | 198 | 0.150 |
Why?
|
| Child, Preschool | 5 | 2024 | 1990 | 0.140 |
Why?
|
| Anticonvulsants | 1 | 2019 | 104 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2018 | 83 | 0.140 |
Why?
|
| Telemedicine | 1 | 2023 | 326 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 2 | 2017 | 75 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2019 | 103 | 0.140 |
Why?
|
| Seizures | 1 | 2019 | 143 | 0.140 |
Why?
|
| Vidarabine | 3 | 2023 | 7 | 0.140 |
Why?
|
| Child | 7 | 2024 | 4526 | 0.140 |
Why?
|
| Bacteremia | 1 | 2018 | 94 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 1644 | 0.140 |
Why?
|
| Histocompatibility Testing | 1 | 2017 | 32 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 163 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2020 | 255 | 0.140 |
Why?
|
| Leukemia, B-Cell | 1 | 2017 | 6 | 0.140 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2017 | 8 | 0.140 |
Why?
|
| Critical Illness | 1 | 2021 | 321 | 0.140 |
Why?
|
| Unrelated Donors | 3 | 2022 | 8 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2017 | 63 | 0.140 |
Why?
|
| Animals | 14 | 2021 | 20663 | 0.140 |
Why?
|
| Lymphoma, Follicular | 1 | 2017 | 16 | 0.130 |
Why?
|
| Immunohistochemistry | 3 | 2025 | 896 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2020 | 338 | 0.130 |
Why?
|
| Siblings | 3 | 2022 | 43 | 0.130 |
Why?
|
| Treatment Failure | 2 | 2020 | 201 | 0.130 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 174 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 641 | 0.130 |
Why?
|
| Survivors | 3 | 2023 | 171 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2009 | 57 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2014 | 108 | 0.130 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 26 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 677 | 0.120 |
Why?
|
| Fluorouracil | 2 | 2009 | 66 | 0.120 |
Why?
|
| Transplantation Chimera | 2 | 2007 | 40 | 0.110 |
Why?
|
| Blood Component Removal | 1 | 2015 | 16 | 0.110 |
Why?
|
| Allografts | 3 | 2020 | 46 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 165 | 0.110 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 35 | 0.110 |
Why?
|
| Benzamides | 1 | 2014 | 65 | 0.110 |
Why?
|
| Piperazines | 1 | 2014 | 81 | 0.110 |
Why?
|
| Heart Failure | 2 | 2019 | 913 | 0.110 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2014 | 33 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2014 | 137 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2025 | 313 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 2458 | 0.100 |
Why?
|
| Alleles | 2 | 2025 | 448 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 509 | 0.100 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 26 | 0.100 |
Why?
|
| Gene Duplication | 1 | 2012 | 34 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2015 | 124 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2012 | 64 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 168 | 0.090 |
Why?
|
| Leukocytes | 1 | 2012 | 103 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 198 | 0.090 |
Why?
|
| Comorbidity | 3 | 2020 | 1120 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 52 | 0.090 |
Why?
|
| Fetal Blood | 2 | 2022 | 73 | 0.090 |
Why?
|
| Blast Crisis | 2 | 2020 | 10 | 0.090 |
Why?
|
| Gene Rearrangement | 2 | 2011 | 41 | 0.080 |
Why?
|
| Obesity | 1 | 2018 | 1235 | 0.080 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2010 | 29 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2022 | 2570 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 422 | 0.080 |
Why?
|
| Helicobacter | 1 | 2009 | 3 | 0.080 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 153 | 0.080 |
Why?
|
| Helicobacter Infections | 1 | 2009 | 55 | 0.080 |
Why?
|
| Mice | 10 | 2014 | 10844 | 0.080 |
Why?
|
| Leucovorin | 1 | 2009 | 9 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2010 | 347 | 0.080 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 21 | 0.080 |
Why?
|
| Infant | 3 | 2019 | 1645 | 0.080 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 5 | 0.080 |
Why?
|
| Remission, Spontaneous | 1 | 2008 | 14 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 89 | 0.070 |
Why?
|
| Carcinoma | 1 | 2009 | 123 | 0.070 |
Why?
|
| Stem Cell Factor | 3 | 2004 | 26 | 0.070 |
Why?
|
| Equipment Failure | 1 | 2008 | 67 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2009 | 498 | 0.070 |
Why?
|
| Time Factors | 4 | 2019 | 3768 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 730 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2008 | 226 | 0.070 |
Why?
|
| Mortality | 2 | 2018 | 160 | 0.070 |
Why?
|
| Cause of Death | 2 | 2020 | 221 | 0.070 |
Why?
|
| Imatinib Mesylate | 2 | 2019 | 34 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 115 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 937 | 0.070 |
Why?
|
| Whole-Body Irradiation | 2 | 2007 | 33 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 2006 | 27 | 0.060 |
Why?
|
| Ubiquinone | 1 | 2006 | 18 | 0.060 |
Why?
|
| Chlorambucil | 1 | 2006 | 3 | 0.060 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2006 | 46 | 0.060 |
Why?
|
| Clone Cells | 1 | 2006 | 114 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 34 | 0.060 |
Why?
|
| Symptom Flare Up | 1 | 2025 | 14 | 0.060 |
Why?
|
| Methylprednisolone | 1 | 2025 | 35 | 0.060 |
Why?
|
| Interleukin-3 | 2 | 2002 | 20 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2009 | 554 | 0.060 |
Why?
|
| Interleukin-11 | 2 | 2002 | 8 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 2575 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 341 | 0.060 |
Why?
|
| Cell Culture Techniques | 2 | 2004 | 182 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2005 | 130 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2012 | 3396 | 0.060 |
Why?
|
| Base Sequence | 2 | 2006 | 1331 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2018 | 3293 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 165 | 0.050 |
Why?
|
| Kinetics | 2 | 2002 | 763 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2002 | 321 | 0.050 |
Why?
|
| Incidence | 2 | 2019 | 1377 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1654 | 0.050 |
Why?
|
| Calcineurin Inhibitors | 1 | 2023 | 23 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1408 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 83 | 0.050 |
Why?
|
| Immunoglobulin Fragments | 1 | 2003 | 7 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2003 | 9 | 0.050 |
Why?
|
| Leukapheresis | 1 | 2003 | 11 | 0.050 |
Why?
|
| Safety-net Providers | 1 | 2023 | 30 | 0.050 |
Why?
|
| Complementarity Determining Regions | 1 | 2003 | 38 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 1991 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2680 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2003 | 182 | 0.050 |
Why?
|
| Inflammation | 1 | 2009 | 1147 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2014 | 988 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 138 | 0.050 |
Why?
|
| Endosomes | 1 | 2003 | 177 | 0.050 |
Why?
|
| Cell Count | 2 | 2019 | 132 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 325 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2003 | 247 | 0.050 |
Why?
|
| Toxocara | 1 | 2021 | 1 | 0.050 |
Why?
|
| Transplantation, Haploidentical | 1 | 2021 | 4 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2002 | 233 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2024 | 346 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 53 | 0.050 |
Why?
|
| Graft Survival | 1 | 2002 | 289 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 415 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 52 | 0.040 |
Why?
|
| Spleen | 1 | 2002 | 483 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2025 | 1007 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 25 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 454 | 0.040 |
Why?
|
| Hydrazines | 1 | 2020 | 10 | 0.040 |
Why?
|
| Benzoates | 1 | 2020 | 8 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 658 | 0.040 |
Why?
|
| Carmustine | 1 | 2020 | 11 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2020 | 37 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 34 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 78 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 2019 | 15 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 99 | 0.040 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2019 | 16 | 0.040 |
Why?
|
| Karyotyping | 2 | 2011 | 48 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 137 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 11 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 772 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 201 | 0.040 |
Why?
|
| Survivorship | 1 | 2018 | 14 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1094 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 187 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 282 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 231 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 1469 | 0.040 |
Why?
|
| United States | 2 | 2022 | 7842 | 0.040 |
Why?
|
| Lymphoma | 1 | 2018 | 103 | 0.040 |
Why?
|
| Filgrastim | 1 | 2017 | 8 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2017 | 15 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 196 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 118 | 0.030 |
Why?
|
| Mice, Mutant Strains | 2 | 2010 | 302 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 31 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 28 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1256 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2012 | 2109 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 58 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2334 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 888 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 254 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 105 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2010 | 229 | 0.030 |
Why?
|
| Karyotype | 1 | 2015 | 18 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2007 | 2157 | 0.030 |
Why?
|
| Liver Failure | 1 | 2015 | 18 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2010 | 519 | 0.030 |
Why?
|
| raf Kinases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2010 | 525 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 24 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2014 | 8 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1558 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2014 | 57 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 121 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2016 | 329 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 71 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 102 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 202 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 374 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 873 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1147 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2007 | 883 | 0.020 |
Why?
|
| Echocardiography | 1 | 2016 | 501 | 0.020 |
Why?
|
| Genes, abl | 1 | 2012 | 9 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 17 | 0.020 |
Why?
|
| PAX5 Transcription Factor | 1 | 2012 | 13 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 443 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 31 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 58 | 0.020 |
Why?
|
| Thrombopoietin | 2 | 2004 | 11 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2079 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 936 | 0.020 |
Why?
|
| Cell Cycle | 2 | 2004 | 392 | 0.020 |
Why?
|
| Cell Division | 2 | 2004 | 450 | 0.020 |
Why?
|
| Genes, APC | 1 | 2010 | 10 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2010 | 51 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 311 | 0.020 |
Why?
|
| Epithelium | 1 | 2010 | 96 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 167 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2010 | 68 | 0.020 |
Why?
|
| Massachusetts | 1 | 2016 | 2075 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 46 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2010 | 79 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2010 | 186 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2010 | 394 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 212 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 921 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 615 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2007 | 8 | 0.020 |
Why?
|
| Ataxin-1 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Ataxins | 1 | 2007 | 5 | 0.020 |
Why?
|
| Succinimides | 1 | 2007 | 17 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2007 | 30 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2007 | 27 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 12 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2007 | 27 | 0.020 |
Why?
|
| H-2 Antigens | 1 | 2007 | 67 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2187 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 40 | 0.020 |
Why?
|
| Coenzymes | 1 | 2006 | 7 | 0.020 |
Why?
|
| Cell Separation | 1 | 2007 | 147 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2006 | 16 | 0.020 |
Why?
|
| ras Proteins | 1 | 2006 | 77 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 197 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2006 | 87 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 242 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 200 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 575 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 216 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 424 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2004 | 55 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 969 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2003 | 158 | 0.010 |
Why?
|
| Membrane Microdomains | 1 | 2003 | 49 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 2004 | 124 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 128 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 209 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 1207 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2003 | 178 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2003 | 182 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 778 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 367 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 401 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 3035 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 837 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2003 | 237 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2002 | 195 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1198 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2002 | 132 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 758 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 1592 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 1277 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1180 | 0.010 |
Why?
|
| Lung | 1 | 2004 | 956 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 895 | 0.010 |
Why?
|